DNDi – Towards an innovative oral combination treatment for visceral leishmaniasis: Preclinical development and selected compounds

• Unité de recherche: DDC
• Numéro de projet: 7F-09973.01

Objectifs du projet (Anglais)

Contexte
Visceral leishmaniasis is a neglected tropical disease and fatal if left untreated in over 95% of cases. Existing therapies have serious drawbacks in terms of safety, drug resistance, field-adapted use, cost, length and tolerability. Drugs for Neglected Disease initiative, a non-profit drug research and development organization, carries out preclinical activities on two drug compounds for the development The overall goal of this project is to contribute to the reduction of the burden of visceral leishmaniasis, one of the most neglected tropical diseases. The preclinical activities targeted with this project will allow preparing the first in-human study of two promising preclinical candidates. If successful, this will ultimately improve therapeutic possibilities for patients affected by visceral leishmaniasis who often are poor people and will help improve their health outcomes
Objectifs
The overall goal of this project is to contribute to the reduction of the burden of visceral leishmaniasis, one of the most neglected tropical diseases. The preclinical activities targeted with this project will allow preparing the first in-human study of two promising preclinical candidates. If successful, this will ultimately improve therapeutic possibilities for patients affected by visceral leishmaniasis who often are poor people and will help improve their health outcomes.
Groupes cibles
The main direct beneficiaries of the project are mainly the poor people affected by or exposed to visceral leishmaniasis in more than 80 countries worldwide and for whom visceral leishmaniasis is potentially fatal if untreated.
Effets à moyen terme
This single phase contributes to the development of a patient-adapted, simple oral therapy for visceral leishmaniasis that is affordable, safe and efficacious in both children and adults.
Résultats
Principaux résultats attendus:   The key outputs of the single phase are the following preclinical activities: 
Manufacturing of clinical supplies for the first in-human study by the end of 2017.
Preparatory activities for the first in -human study for two preclinical candidates.

Principaux résultats antérieurs:   Not applicable (single phase)

Direction/office fédéral responsable
DDC
Crédit
Coopération au développement
Partenaire de projet
Partenaire contractuel
Organisation suisse à but non lucratif
Autre organisation suisse non-profit



Coordination avec d'autres projets et acteurs
Product Development Partnerships (PDPs) in Geneva supported by SDC: Medicines for Malaria Venture (MMV), Foundation for Innovative New Diagnostics (FIND), as well as the Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO).
Budget
Phase en cours
Budget de la Suisse
CHF   500'000
Budget suisse déjà attribué
CHF   400'000
Détails techniques supplémentaires